Glucocorticoid-induced osteoporosis

Endocrinology and Metabolism Clinics of North America

Volumn 32, Issue 1, 2003, Pages 135-157

  Saag, Kenneth G ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTRADIOL; ESTROGEN; ETIDRONIC ACID; FLUORIDE; GLUCOCORTICOID; GROWTH FACTOR; HYDROCHLOROTHIAZIDE; PAMIDRONIC ACID; PARATHYROID HORMONE; PREDNISONE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TESTOSTERONE; THIAZIDE DIURETIC AGENT; VITAMIN D;

ASTHMA; BONE DENSITY; BONE MINERAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIURETIC THERAPY; DRUG INDUCED DISEASE; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN DEFICIENCY; HUMAN; META ANALYSIS; OSTEOPOROSIS; PATHOGENESIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; STEROID THERAPY; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 0037299457     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(02)00064-6     Document Type: Review

References (182)

1. Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96:115-23.
2. Morgan S, Saag K, Julian B, et al. Osteopenic bone diseases. In: Koopman WJ, editor. Arthritis and allied conditions. 14th edition. Philadelphia: Williams & Wilkins; 2000. p. 2413, 2425, 2249.
3. Saag K, Kirwin J. Glucocortiocoid therapy in rheumatoid arthritis. In: Tsokos G, editor. Modern therapeutics of rheumatoid diseases, Totowa, NJ: Humana Press; 2001.
4. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.
5. Christensen PM, Kristiansen IS, Brosen K, et al. Use of prednisolone and concurrent pharmacological prevention of osteoporosis. Arthritis Rheum 1999;42:S289.
6. Mudano A, Allison J, Hill J, et al. Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort. J Rheumatol 2001;28:1298-305.
7. Walsh LJ, Wong CA, Pringle M, et al. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996;313:344-6.
8. Laan RFJM, Buijs WCAM, van Erning LJT, et al. Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content. Calcif Tissue Int 1993;52:5-9.
9. LoCascio V, Bonnucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1992;8:39-51.
10. LoCasio V, Bonucci E, Imbimbo B, et al. Bone loss after glucocorticoid therapy. Bone Miner 1984;8:39-51.
11. Reid IR, Evans MC, Wattie DJ, et al. Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients. Osteoporos Int 1992;2:103-5.
12. Verstraeten A, Dequeker J, Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 1986;45:852-7.
13. Dykman TR, Gluck OS, Murphy WA, et al. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1985;28:361-8.
14. Hall GM, Spector TD, Griffin JA, et al. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women, Arthritis Rheum 1993;36:1510-6.
15. Kroger H, Honaken R, Saarikoski S, et al. Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis-a population based study. Ann Rheum Dis 1994;53:18-23.
16. Lane NE, Pressman AR, Star VL, et al. Rheumatoid arthritis and bone mineral density in elderly women. J Bone Miner Res 1995;10:257-63.
17. Messina OD, Barreira JC, Zanchetta JR, et al. Effect of low doses of deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis. J Rheumatol 1992;19:1520-6.
18. Sambrook PN, Eisman JA, Yeates MG, et al. Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids. Ann Rheum Dis 1986;45:950-3.
19. Buckley LM, Leib ES, Cartularo KS, et al. Effects of low dose glucocorticoids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1995;22:1055-9.
20. Garton MJ, Reid DM. Bone mineral density of the hip and of the anteroposterior and lateral dimensions of the spine in men with rheumatoid arthritis: effects of low-dose corticosteroids. Arthritis Rheum 1993;36:222-8.
21. Reid IR, Grey AB. Corticosteroid osteoporosis. Baillieres Clin Rheumatol 1993;7:573-87.
22. McEvoy CE, Ensrud KE, Bender E, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:704-9.
23. Pearce G, Tabensky A, Delmas PD, et al. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 1998;83:801-6.
24. Saito JK, Davis JW, Wasnich RD, et al. Users of low-dose glucocorticoids have increased bone loss rates: a longitudinal study. Calcif Tissue Int 1995;57:115-9.
25. Als OS, Gotfredsen A, Christiansen C. The effect of glucocorticoids on bone mass in rheumatoid arthritis patients. Arthritis Rheum 1985;28:369-75.
26. Cetin A, Celiker R, Dincer F, et al. Bone mineral density in children with juvenile chronic arthritis. Clin Rheum 1998;17:551-3.
27. de Nijs RNJ, Jacobs JWG, Gijlsma JWJ, et al. Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology 2001;40:1375-83.
28. Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Arth Rheum 2000;43:522-30.
29. Gough A, Sambrook P, Devlin J, et al. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 1998;25:1282-9.
30. Gough KS, Lilley J, Eyre S, et al. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994;344:23-7.
31. Hansen M, Florescu A, Stoltenberg M, et al. Bone loss in rheumatoid arthritis. Influence of disease activity, duration of the disease, functional capacity, and corticosteroid treatment. Scand J Rheumatol 1996;25:367-76.
32. Suzuki Y, Mizushima Y. Osteoporosis in rheumatoid arthritis. Osteoporos Int 1997;7(Suppl):S217-S22.
33. Towheed TE, Brouillard D, Yendt E, et al. Osteoporosis in rheumatoid arthritis: findings in the metacarpal, spine, and hip and a study of the determinants of both localized and generalized osteopenia. J Rheumatol 1995;22:440-3.
34. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995;54:49-52.
35. Spector TD, Hall GM, McCloskey EV, et al. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ 1993;306:558.
36. Ebeling PR, Erbas B, Hopper JL, et al. Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids. J Bone Miner Res 1998;13:1283-9.
37. Ruegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss: a longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 1983;25:615-20.
38. Schatz M, Dudl J, Zeiger RS, et al. Osteoporosis in corticosteroid-treated asthmatic patients: clinical correlates. Allergy Proc 1993;14:341-5.
39. Villareal MS, Klaustermeyer WB, Hahn TJ, et al. Osteoporosis in steroid-dependent asthma. Ann Allergy Asthma Immunol 1996;76:369-72.
40. Iqbal F, Michaelson J, Thaler L, et al. Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and bonadal function. Chest 1999;116:1616-24.
41. Andreassen H, Rungby J, Dahlerup JF, et al. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 1997;32:1247-55.
42. Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Ann Intern Med 2000;133:795-9.
43. Bernstein CN, Seeger LL, Sayre JW, et al. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995;10:250-6.
44. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987;28:410-5.
45. Olgaard K, Storm T, van Wowern N, et al. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort. Calcif Tissue Int 1992;50:490-4.
46. Dolan AL, Moniz C, Dasgupta B, et al. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum 1997;40:2022-9.
47. Rizzato G, Tosi G, Mella C, et al. Prednisone-induced bone loss in sarcoidosis: a risk especially frequent in postmenopausal women. Sarcoidosis 1988;5:93-6.
48. Kipen Y, Buchbinder R, Forbes A, et al. Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids. J Rheumatol 1997;24:1922-9.
49. Ramsey-Goldman R, Dunn JE, Huang C-F, et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 1999;42:882-90.
50. Zonana-Nacach A, Barr SG, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arth Rheum 2000;43:1801-8.
51. Epstein S, Shane E, Bilezikian JP. Organ transplantation and osteoporosis. Curr Opin Rheumatol 1995;7:255-61.
52. Julian BA, Laskow DA, Dubovsky J, et al. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991;325:544-50.
53. Ponticelli C, Aroldi A. Osteoporosis after organ transplantation. Lancet 2001;357:1623.
54. Ramsey-Goldman R, Dunn JE, Dunlop DD, et al. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res 1999;14:456-63.
55. Rodino MA, Shane E. Osteoporosis after organ transplantation. Am J Med 1998;104:459-69.
56. Saag KG. Osteoporosis in rheumatoid arthritis: the role of glucocorticoids. Rheum Arthritis Ind Rev 1999;II:3-5.
57. Leboff MS, Wade JP, Mackowiak S, et al. Low dose prednisone does not affect calcium homeostasis or bone density in postmenopausal women with rheumatoid arthritis. J Rheumatol 1991;18:339-44.
58. Sambrook PN, Cohen ML, Eisman JA, et al. Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study. Ann Rheum Dis 1989;48:535-8.
59. Sambrook PN, Eisman J, Champion GD, et al. Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum 1987;30:721-8.
60. Verhoeven MC, Boers M. Limited bone loss due to corticosteroids: a systematic review of prospective studies in rheumatoid arthritis and other diseases. J Rheumatol 1997;24:1495-503.
61. Nielsen HK, Charles P, Mosekilde L. The effect of single oral doses of prednisone on the circadian rhythm of serum ostecalcin in normal subjects. J Clin Endocrinol Metab 1988;67:1025.
62. Emkey RD, Lindsay R, Lyssy J, et al. The systemic effect of intraarticular administration of corticosteroid on markers on bone formation and bone resorption in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:277-82.
63. Marystone JF, Barrett-Connor EL, Morton DJ. Inhaled and oral corticosteroids: their effects on bone mineral density in older adults. Am J Public Health 1995;85:1693-5.
64. Toogood JH, Baskerville JC, Markov AE, et al. Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J Allergy Clin Immunol 1995;96:157-66.
65. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoidso n bone density in premenopausal women. N Engl J Med 2001;345:941-7.
66. Wong CA, Walsh LJ, Smith CJP, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000;355:1399-403.
67. van Staa TP, Leufkens H, Cooper C. Use of inhaled corticosteroids and risks of fractures. J Bone Miner Res 2001;16:581-8.
68. Peel NFA, Moore DJ, Barrington NA, et al. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 1995;54:801-6.
69. Luengo M, Picado C, Del Rio L, et al. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 1991;46:803-6.
70. Evans SF, Davie MWJ. Vertebral fractures and bone mineral density in idiopathic, secondary and corticosteroid associated osteoporosis in men. Ann Rheum Dis 2000;59:269-75.
71. Naganatham V, Jones G, Nash P, et al. Vertebral fracture risk with long-term corticosteroid therapy. Arch Int Med 2000;160:2917-22.
72. Selby PL, Halsey JP, Adams KRH, et al. Corticosteroids do not alter the threshold for vertebral fracture. J Bone Miner Res 2000;15:952-6.
73. Baltzan MA, Suissa S, Bauer DC, et al. Hip fractures attributable to corticosteroid use. Lancet 1999;353:1327.
74. Lems WF, Jahangier ZN, Jacobs JWG, et al. Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. Clin Exp Rheumatol 1995;13:293-7.
75. McDougall R, Sibley J, Haga M, et al. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheum 1994;21:1207-13.
76. Michel BA, Bloch DA, Wolfe F, et al. Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheum 1993;20:1666-9.
77. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309:265-8.
78. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-18.
79. Saag KG, Emkey R, Schnitzer T, et al. Alendronate for the treatment and prevention of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
80. van Everdingen AA, Jacobs JWG, van Reesema DR, et al. Low dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease modifying properties and side effects: a double-blind placebo-controlled clinical trial. Ann Intern Med 2002;136:1-12.
81. Reid DM, Hughes R, Laan RF. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000;15:1006-13.
82. Gluck OS, Murphy WA, Hahn TJ, et al. Bone loss in adults receiving alternate day glucocorticoid therapy. Arthritis Rheum 1981;24:892-8.
83. Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med 1990;150:2545-8.
84. van Staa TP, Leukens HGM, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000;39:1383-9.
85. Van Staa T, Leufkens H, Abenhaim L, et al. Use of oral coticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
86. Adachi JD, Bensen WG, Hodsman AB. Corticosteroid-induced osteoporosis. Semin Arthritis Rheum 1993;22:375-84.
87. Canalis E. Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 1996;81:3441-7.
88. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 1994;20:629-50.
89. Ishida Y, Heersche JNM. Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. J Bone Miner Res 1998;13:1822-6.
90. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999;14:1061-6.
91. Carbonare L, Arlot ME, Chavassieux PM, et al. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 2001;16:97-103.
92. Dempster DW, Arlot MA, Meunier PJ. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 1983;35:410-7.
93. Weinstein RS, Jilka RL, Parfitt AM, et al. Inhibition of osteoblastogenesis and promotion of apotosis of osteoblast and osteocytes by glucorticoids. J Clin Invest 1998;102:274-82.
94. Godschalk M, Levy J, Downs RW. Glucocorticoids decrease vitamin D receptor numbers and gene expression in human osteosarcoma cells. J Bone Miner Res 1992;7:21.
95. Kotowicz MA, Hall S, Hunder GG, et al. Relationship of glucocorticoid dosage to serum bone gla-protein concentration in patients with rheumatologic disorders. Arthritis Rheum 1990;33:1487-92.
96. Hahn TJ, Halstead LR, Baran DT. Effects of short-term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab 1981;52:111-5.
97. Morris HA, Need AG, O'Loughlin PD, et al. Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int 1990;46:305-8.
98. Neilsen HK, Thomsen K, Eriksen EF, et al. The effects of high-dose glucocorticoid administration on serum bone gamma carboxyglutamic acid containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects. Bone Miner 1988;4:105.
99. Suzuki Y, Ichikawa Y, Saito E, et al. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983;32:151-6.
100. Doerr P, Pirke KM. Cortisol-induced suppression of plasma testosterone in normal adult males. J Clin Endocrinol Metab 1976;43:622.
101. MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986;104:648-54.
102. Sakakura M, Takebe K, Nakagawa S. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab 1975;40:774.
103. Hofbauer LC, Gori F, Riggs L, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999;140:4382-9.
104. Sasaki N, Kusano E, Ando Y, et al. Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. Nephrol Dial Transplant 2001;16:479-82.
105. Hansen M, Podenphant J, Florescu A, et al. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis: clinical benefits and skeletal side effects. Ann Rheum Dis 1999;58:713-8.
106. Administration HCF, 42 CFR Part 410, et al. Medicare program coverage of and payment for bone mass measurements. Federal Register 1998;63:34320-8.
107. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001;44:1496-503.
108. Eastell R, Reid DM, Compston J, et al. A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998;244:271-92.
109. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis Belle, Mead, New Jersey: Excerpta Medica Inc; 1998.
110. Sturtridge W, Lentle B, Hanley DA. The use of bone density measurement in the diagnosis and management of osteoporosis. Can Med Assoc J 1996;155:924-92.
111. Adachi JD, Olszynski WP, Hanley DA, et al. Management of corticosteroid-induced osteoporosis. Sem Arth Rheum 2000;29:228-51.
112. Sambrook PN, Diamond T, Ferris L, et al. Corticosteroid induced osteoporosis: guidelines for treatment. Australian Fam Phys 2001;30:793-6.
113. Pocock NA, Eisman JA, Dunstan CR, et al. Recovery from steroid-induced osteoporosis. Ann Intern Med 1987;107:319.
114. Gray R, Doherty SM, Galloway J, et al. A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum 1991;34:287-95.
115. Reid IR, Ibbertson HK. Calcium supplements in the prevention of steroid-induced osteoporosis. Am J Clin Nutr 1986;44:287-90.
116. Bernstein CN, Seeger LL, Anton PA, et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 1996;10:777-86.
117. Braun JJ, Birkenhager-Frenkel DH, Rietvoeld AH, et al. Influence of 1 alpha-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; a double blind controlled study. Clin Endocrinol 1983;18:265-73.
118. Reginster JY, Kuntz D, Verdickt W, et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999;9:75-81.
119. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993;328:1747-52.
120. Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 1996;125:961-8.
121. Bijlsma JWJ, Raymakers JA, Mosch C, et al. Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia. Clin Exper Rheumatol 1988;6:113-9.
122. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
123. Amin S, LaValley MP, Simms RW, et al. The role of vitamin D in corticosteroid-induced osteoporosis. Arthritis Rheum 1999;42:1740-51.
124. Homik J, Suarez-Almazor M, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis (Cochrane review). In: The Cochrane library, vol issue 1. Oxford: Update Software; 1999.
125. Adams JS, Wahl TO, Lukert BP. Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients. Metabolism 1981;30:217-21.
126. Adachi JD, Bensen WG, Bell MJ, et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 1997;36:255-7.
127. Montemurro L, Schiraldi G, Fraioli P, et al. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991;49:71-6.
128. Healey JH, Paget SA, Williams-Russo P, et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 1996;58:73-80.
129. Luengo M, Pons F, Martinez de Osaba MJ, et al. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study. Thorax 1994;49:1099.
130. Ringe J-D, Welzel D. Salmon calcitonin in the therapy of corticosteroid-induced osteoporosis. Eur J Clin Pharmacol 1987;33:35-9.
131. Kotaniemi A, Piirainen H, Paimela L, et al. Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy? J Rheumatol 1996;23:1875-9.
132. Hall GM, Daniels M, Doyle DV, et al. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994;37:1499-505.
133. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992;7:1063-9.
134. Sambrook P, Birmingham J, Champion D, et al. Postmenopausal bone loss in rheumatoid arthritis: effect of estrogens and androgens. J Rheumatol 1992;19:357-61.
135. Reid IR, Wattie DJ, Evans MC, et al. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996;156:1173-7.
136. Grecu EO, Weinshelbaum A, Simmons R. Effective therapy of glucocorticoid-induced osteoporosis with medroxyprogesterone acetate. Calcif Tissue Int 1990;46:294-9.
137. Adachi JD, Cranney A, Goldsmith CH, et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol 1994;21:1922-6.
138. Bird HA, Hill J, Sitton NG, et al. A clinical and biochemical assessment of etidronate disodium in patients with active rheumatoid arthritis. Clin Rheumatol 1988;7:91-4.
139. Diamond T, McGuigan L, Barbagallo S, et al. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 1995;98:459-63.
140. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994;33:348-50.
141. Riemens SC, Oostdijk A, van Doormaal JJ, et al. Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidol. Osteoporos Int 1996;6:213-8.
142. Sebaldt RJ, Ioannidis G, Adachi JD, et al. 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis. J Rheumatol 1999;26:1545-9.
143. Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995;99:235-42.
144. Wolfhagen FH, vanBuuren HR, denOuden JW, et al. Cyclic etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. J Hepatol 1997;26:325-30.
145. Geusens P, Dequeker J, Vanhoof J, et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment: a double blind, randomised placebo controlled study. Ann Rheum Dis 1998;57:724-7.
146. Jenkins EA, Walker-Bone KE, Wood A, et al. The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. Scand J Rheumatol 1999;28:152-6.
147. Pitt P, Todd P, Webber D, et al. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long term oral corticosteroid treatment. Thorax 1998;53:351-6.
148. Roux C, Oriente P, Laan R, et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 1998;83:1128-33.
149. Skingle SJ, Crisp AJ. Increased bone density in patients on steroids with etidronate. Lancet 1994;344:543-4.
150. Adachi JD, Roux C, Pitt PI, et al. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. J Rheumatol 2000;27:2424-31.
151. Falcini F, Trapani S, Ermini M, et al. Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling. Calcif Tissue Int 1996;58:166-9.
152. Gonnelli S, Rottoli P, Cepollaro C, et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 1997;6:382-5.
153. Adachi R, Saag K, Emkey R, et al. Effects of alendronate for two years on BMD and fractures in patients receiving glucocorticoids. Arthritis Rheum 2001;44:202-11.
154. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-85.
155. Boutsen Y, Jamart J, Esselinckx W, et al. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif Tissue Int 1997;61:266-71.
156. Boutsen Y, Jamart J, Esselnickx W, et al. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 2001;16:104-12.
157. Gallacher SJ, Fenner JAK, Anderson K, et al. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. Thorax 1992;47:932-6.
158. Reid IR, King AR, Alexander CJ, et al. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD). Lancet 1988;1:143-6.
159. Valkema R, Vismans F-JE, Papapoulos SE, et al. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 1989;5:183-92.
160. Greenwald M, Brandli D, Spector S, et al. Corticosteroid-induced osteoporosis: effects of a treatment with slow-release sodium fluoride. Osteoporos Int 1992;2:303-4.
161. Guaydier-Souquires G, Kotzi PO, Sabatier JP, et al. In corticsteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study. Osteopros Int 1996;6:171.
162. Lems WF, Jacobs WG, Bijlsma JWJ, et al. Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis. Osteoporos Int 1997;7:575-82.
163. Rizzoli R, Chevalley T, Slosman DO, et al. Sodium monfluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis. Osteoporos Int 1995;5:39-46.
164. Lems WF, Jacobs JWG, Bijlsma JWJ, et al. Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Ann Rheum Dis 1997;56:357-63.
165. Adami S, Fossaluzza V, Rossini M. Prevention of corticosteroid-induced osteoporosis with nandrolone decanoate. Bone Miner 1991;15:73.
166. Tanaka H, Seino Y. Does growth hormone treatment prevent corticosteroid-induced osteoporosis? Bone 1996;18:493-4.
167. Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: results of a randomized controlled clinical trial. J Clin Invest 1998;102:1627-33.
168. Neer R, Arnaud C, Zanchetta J, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
169. Aagaard EM, Lin P, Modin GW, et al. Prevention of glucocorticoid-induced osteoporosis: provider practice at an urban county hospital. Am J Med 1999;107:456-60.
170. Buckley LM, Marquez M, Hudson JO, et al. Variations in physician perceptions of the risk of osteoporosis in corticosteroid users by physician specialty. J Rheumatol 1998;25:2195-202.
171. Nair B, Sibley J, Haga M. Osteoporosis (OP) prevention in patients on continuous oral corticosteroid therapy among internal medicine specialists. Arthritis Rheum 1997;40 (Suppl):S309.
172. Osiri M, Saag KG, Ford AM, et al. Practice pattern variation among internal medicine specialists in the prevention of glucocorticoid-induced osteoporosis. J Clinical Rheumatol 2000;6:117-22.
173. Soucy E, Bellamy N, Adachi JD, et al. A Canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists. J Rheumatol 2000;27:1506-12.
174. Yood RA, Harrold LR, Fish L, et al. Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. Arch Intern Med 2001;161:1322-7.
175. Buckley LM, Marquez M, Feezor R, et al. Prevention of corticosteroid-induced osteoporosis. Arthritis Rheum 1999;42:1736-9.
176. Solomon DH, Kuntz KK. Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? Arthritis Rheum 2000;43:1967-75.
177. Kvein TK, Haugeberg G, Uhlig T, et al. Data driven attempt to create a clinical algorithm for identification of women with rheumatoid arthritis at high risk for osteoporosis. Ann Rheum Dis 2000;59:805-11.
178. Harris ST, Eriksen EF, Davidson M, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001;86:1890-7.
179. Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999;84:3076-81.
180. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995;99:36-42.
181. Lyritis GP, Paspati I, Karachalios T, et al. Pain relief from nasal salmon calcitonin in osteoporositc vertebral crush fractures: a double blind, placebo controlled clinical study. Acta Orthopedica Scandinavica Supplementum 1997;275:112-4.
182. Pun KK, Chan LW. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Therapeutics 1989;11(2):205-9.